Home / Guides / Tirzepatide results timeline
What to expect.
Tirzepatide results timeline: what to expect, month by month
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
Tirzepatide starts at 2.5 mg and steps up every 4 weeks or more, so the first months are about adjusting. In Zepbound’s 72-week SURMOUNT-1 trial, average weight loss was 15.0% to 20.9% by dose (label read November 2, 2026); compounded tirzepatide wasn’t studied.
- Weeks 1–4: 2.5 mg, a starting dose for adjusting
- Weeks 5–20: steps of 2.5 mg, at least 4 weeks apart
- Week 21 on: the earliest a 15 mg dose can start
What are the tirzepatide milestones, from week 1 to week 72?
- Weeks 1–4
- 2.5 mg, the starting dose
- Weeks 5–20
- Stepping up, 2.5 mg every 4+ weeks
- Weeks 21–72
- Maintenance, at least 52 weeks in Study 1
- Week 72
- Results measured, the end of Study 1
Questions about your progress? Call or text
4.8 out of 5 on Trustpilot · LegitScript certified
About 3 minutes of health questions. No insurance needed.
Compounded medicines aren’t FDA-approved. A NexLife provider prescribes one only if it offers a significant difference for you compared with an FDA-approved medicine.
At a glance
Tirzepatide results timeline at a glance
The short answers, from Zepbound’s label. Each one is explained below.
| Question | Answer |
|---|---|
| Weeks 1 to 4? | 2.5 mg a week, a starting dose. Blood levels take about 4 weeks to settle on a dose. |
| After that? | The dose can rise by 2.5 mg after at least 4 weeks at each step. |
| When can 15 mg start? | Week 21, at the earliest. |
| Results at week 72? | Average loss of 15.0% to 20.9% by dose in Zepbound’s SURMOUNT-1 trial, versus 3.1% on placebo. |
| How many lost 20% or more? | More than half on 15 mg (56.7%), versus 3.1% on placebo. |
| What if you stop? | In SURMOUNT-4, weight rose 14.0% in the year after people switched to placebo. |
Trial averages for FDA-approved Zepbound, not a forecast for you. Compounded tirzepatide wasn’t studied, and it isn’t FDA-approved.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Results build over months: in Zepbound’s 72-week SURMOUNT-1 trial, average loss was 15.0% to 20.9% by dose, versus 3.1% on placebo.
- Weeks 1 to 4 are for adjusting, on 2.5 mg. Then 2.5 mg steps; 15 mg can’t start before week 21.
- 9 in 10 on 15 mg lost at least 5% in that trial, and 56.7% lost at least 20%.
- Stopping reverses some of it: in SURMOUNT-4, weight rose 14.0% in the year after switching to placebo.
- These are trial averages for FDA-approved Zepbound. Compounded tirzepatide wasn’t studied. An average describes a group, not you.
- At NexLife, compounded tirzepatide is $139 a month on the 12-month plan, or $169 month to month, at every dose.
The timeline
What’s the tirzepatide results timeline, month by month?
From the Zepbound prescribing information; compounded tirzepatide wasn’t studied. Your own pace depends on your dose, your body and your habits.
Getting started. 2.5 mg a week, a starting dose that isn’t meant for the long term. It takes about 4 weeks for blood levels to settle on a dose. Stomach side effects are most likely while the dose is going up.
Stepping up. The dose can rise by 2.5 mg after at least 4 weeks at each step. The earliest 15 mg can start is week 21. Your provider sets the pace; some people stay longer at a dose.
At your maintenance dose. In Study 1, people spent at least 52 weeks on their maintenance dose (5, 10 or 15 mg) before results were measured at week 72.
The trial endpoint. In Study 1, average loss was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, versus 3.1% on placebo.
What Study 4 found. People who took it for 36 weeks and were then switched to placebo regained 14.0% of their weight over the next 52 weeks; those who kept taking it lost another 5.5%.
“Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026
Dose steps
How does the dose step up, week by week?
Slowly, by design. On Zepbound’s label, every dose is once a week, and each step comes after at least 4 weeks on the dose before. Your provider sets the pace; some people stay longer at a dose.
- Weeks 1 to 4: 2.5 mg. A starting dose, not one to stay on.
- Then 5 mg. After 4 weeks, the label’s next step is 5 mg.
- Steps of 2.5 mg. Each one after at least 4 weeks on the dose before, as your provider decides.
- 15 mg at most. The earliest it can start is week 21.
- Your maintenance dose. 5, 10 or 15 mg. In Study 1, people spent at least 52 weeks on theirs before results were measured at week 72.
The label’s dose steps, in order. Your prescriber sets your own schedule; your label and prescription come first.
“After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026
| Weekly dose | Volume at 25 mg/mL (example) | Units on a U-100 syringe |
|---|---|---|
| 2.5 mg | 0.1 mL | 10 units |
| 5 mg | 0.2 mL | 20 units |
| 7.5 mg | 0.3 mL | 30 units |
| 10 mg | 0.4 mL | 40 units |
| 12.5 mg | 0.5 mL | 50 units |
| 15 mg | 0.6 mL | 60 units |
The math: mL = dose ÷ strength (mg per mL); units = mL × 100. So 5 mg ÷ 25 mg/mL = 0.2 mL, or 20 units. 25 mg/mL is an example only: it’s the strength of Zepbound’s 15 mg multi-dose vial on its August 2026 FDA label. Your vial’s label decides the strength, and your prescription sets your dose.
Milestones
How many people reached each weight-loss milestone on tirzepatide?
| Weight lost | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| 5% or more | 34.5% | 85.1% | 88.9% | 90.9% |
| 10% or more | 18.8% | 68.5% | 78.1% | 83.5% |
| 15% or more | 8.8% | 48.0% | 66.6% | 70.6% |
| 20% or more | 3.1% | 30.0% | 50.1% | 56.7% |
Zepbound label, Table 2. These numbers come from trials of FDA-approved Zepbound. Compounded tirzepatide isn’t FDA-approved and wasn’t studied in them.
“However, compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.”
U.S. Food and Drug Administration, FDA’s Concerns with UnapprovedGLP-1 Drugs Used for Weight Loss
- 9 in 10on 15 mg lost at least 5%
- More than halfon 15 mg lost at least 20%
- 3.1%average loss on placebo
What changes the pace
What affected tirzepatide results in the trials?
Your dose
Higher maintenance doses led to more weight loss on average: 15.0% on 5 mg vs 20.9% on 15 mg.
Type 2 diabetes
People with type 2 diabetes lost less on average: 12.8% on 10 mg and 14.7% on 15 mg in Study 2.
Staying on it
Stopping after 36 weeks led to regaining 14.0% over the next year in Study 4. Continuing led to more loss.
Your habits
Every trial group had diet and activity advice. In Studies 1 and 2, that meant a reduced-calorie diet (about 500 calories a day less) and a recommended 150 minutes or more of activity a week.
These trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Stop or continue?
What happens if you stop tirzepatide?
| Group | Change |
|---|---|
| Kept taking tirzepatide | −5.5% |
| Switched to placebo | +14.0% |
After 36 weeks on tirzepatide (20.9% lost on average), 670 people were randomly assigned to keep taking it or switch to placebo for 52 more weeks; people who stopped earlier weren’t included. Zepbound label, Table 6.
Thinking about stopping? Talk with your provider first. They can help you plan your next steps, and you can call or text us 24/7 at
What would you pay with NexLife?
Tap where you are now. We’ll show your NexLife price next to it, or tell you we’ll match it.
Pick one above to see your price.
Prices from each provider’s own site, checked November 1, 2026. Brand-name and compounded medications are different products: compounded medications aren’t FDA-approved, and a provider prescribes one only when it offers a significant difference for you. Price Match Guarantee† terms apply.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Tirzepatide results timeline: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
How fast does tirzepatide work?
Gradually, over months rather than weeks. Blood levels settle after about 4 weeks on a dose, and doses step up every 4 weeks or more. In the Zepbound trials, weight loss built over months, and results were measured at 72 weeks.
How much weight can I lose on tirzepatide in a month?
The trials don’t give a monthly figure: they reported results at 36 and 72 weeks. Averaged over 72 weeks, the 15 mg group’s 20.9% works out to about 0.3% of body weight a week, but real loss isn’t that even. These were trials of FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
What results can I expect after 3 months?
At 3 months you’re typically still stepping up the dose: each step comes after at least 4 weeks on the last one, and 15 mg can’t start before week 21. In Study 1, results were measured at week 72, after at least 52 weeks at a maintenance dose. Your provider can tell you what your progress means.
How many people lost at least 20% of their weight in tirzepatide’s trial?
About half on the highest dose. In Study 1, 56.7% of people on 15 mg lost at least 20% of their weight by week 72, as did 50.1% on 10 mg and 30.0% on 5 mg, versus 3.1% on placebo. That trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
What happens if I stop taking tirzepatide?
Some of the weight usually comes back. In Study 4, people switched to placebo after 36 weeks regained 14.0% of their weight over the next year on average, while people who continued lost another 5.5%. Talk with your provider before you stop; they can help you plan next steps.
Will compounded tirzepatide give the same results?
No one can say: compounded tirzepatide hasn’t been studied in clinical trials, and it isn’t FDA-approved, so the FDA hasn’t reviewed it for safety, effectiveness or quality. The results on this page come from trials of FDA-approved Zepbound, and they’re averages for a group, not a forecast for you.
Does tirzepatide work as well with type 2 diabetes?
On average, people with type 2 diabetes lost less in Zepbound’s trials: 12.8% on 10 mg and 14.7% on 15 mg in Study 2. These are trial averages for FDA-approved Zepbound; compounded tirzepatide wasn’t studied, and an average describes a group, not you.
Does a higher tirzepatide dose mean more weight loss?
On average, yes. In Zepbound’s 72-week SURMOUNT-1 trial, average loss was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, versus 3.1% on placebo. Compounded tirzepatide wasn’t studied, and your provider sets the pace of your dose steps.
Do you need to diet and exercise on tirzepatide?
The trials paired it with both: every group had diet and activity advice. In Studies 1 and 2, that meant a reduced-calorie diet (about 500 calories a day less) and a recommended 150 minutes or more of activity a week. Compounded tirzepatide wasn’t studied.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
“In this trial, those randomized to receive the highest approved dosage of Zepbound (15 mg once weekly) lost on average 18% of their body weight compared to those randomized to placebo.”
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Checked every number against the Zepbound prescribing information (revised August 2026), Tables 2 and 6.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Paying less elsewhere? We match it.†
Results take months. Your price stays put.
Compounded tirzepatide $139 a month on a 12-month plan, or $169 month to month, at every dose. Start online in about 3 minutes.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information.
- The New England Journal of Medicine. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), 2022.
- NexLife. Compounded tirzepatide plans.
- U.S. Food and Drug Administration. FDA’s concerns with unapproved
GLP-1 drugs used for weight loss. - Novo Nordisk. Wegovy (semaglutide) prescribing information.
- LegitScript. LegitScript certification record for NexLife.us.
- NexLife. Compounded semaglutide plans.
- Ro: weight loss program pricing. Checked November 1, 2026.
- Hims: Zepbound KwikPen. Checked November 1, 2026.
- Hims: Wegovy pill and pen, with membership. Checked November 1, 2026.
- Mochi Health: FAQs (membership and medication prices). Checked November 1, 2026.
- Embody: compounded tirzepatide, one-month supply. Checked November 1, 2026.
- Embody: compounded semaglutide, one-month supply. Checked November 1, 2026.
- Eli Lilly and Company, via Drugs@FDA. ZEPBOUND (tirzepatide) injection, for subcutaneous use: prescribing information, revised August 2026. Read November 2, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Read November 2, 2026.
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Read November 2, 2026.